Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caredx Inc (NQ: CDNA )

28.12 -0.42 (-1.47%)
Streaming Delayed Price Updated: 3:00 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Caredx Inc

< Previous 1 2 3 4 5 6 7 8 Next >
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care
From CareDx, Inc.
Via Business Wire
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
From CareDx, Inc.
Via Business Wire
CareDx Reports Second Quarter 2023 Results
From CareDx, Inc.
Via Business Wire
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
From CareDx, Inc.
Via Business Wire
CareDx to Report Second Quarter 2023 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance
From CareDx, Inc.
Via Business Wire
CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company
From CareDx, Inc.
Via Business Wire
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
From CareDx, Inc.
Via Business Wire
CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
From CareDx, Inc.
Via Business Wire
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
From CareDx, Inc.
Via Business Wire
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum
From CareDx, Inc.
Via Business Wire
CareDx Reports First Quarter 2023 Results
From CareDx, Inc.
Via Business Wire
CareDx to Report First Quarter 2023 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference
From CareDx, Inc.
Via Business Wire
CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation
From CareDx, Inc.
Via Business Wire
National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community
From CareDx, Inc.
Via Business Wire
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
From CareDx, Inc.
Via Business Wire
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
From Miromatrix Medical Inc.
Via GlobeNewswire
CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association
From CareDx, Inc.
Via Business Wire
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
From Kahn Swick & Foti, LLC
Via Business Wire
The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance
From CareDx, Inc.
Via Business Wire
CareDx Update Regarding Raymond James & Associates’ Conference
From CareDx, Inc.
Via Business Wire
CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
From CareDx, Inc.
Via Business Wire
CareDx Comments on MolDX Publication of New Billing and Coding Article
From CareDx, Inc.
Via Business Wire
CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit
From CareDx, Inc.
Via Business Wire
CareDx Reports Fourth Quarter and Full Year 2022 Results
From CareDx, Inc.
Via Business Wire
CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting
From CareDx, Inc.
Via Business Wire
CareDx to Report Fourth Quarter and Full Year 2022 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings
From CareDx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.